Coherus生物科技

CHRS NASDAQ
21.49
+0.15
+0.70%
交易中 10:14 06/25 EDT
开盘
21.47
昨收
21.34
最高
21.98
最低
20.75
成交量
16.85万
成交均量(3M)
88.21万
52周最高
22.03
52周最低
8.32
换手率
0.24%
市值
14.91亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Coherus生物科技 CHRS股票价格,Coherus生物科技股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
展开 >

最近浏览

名称
价格
涨跌幅